Gary Pace

Gary W.
Pace was the founder of Transcend Therapeutics, Inc., founded in 1992, and Sova Pharmaceuticals, Inc., founded in 2010, where he served as Director in 2010.
Current jobs include Executive Chairman at View Point Medical, Inc.; Director at Protiveris, Inc., NeuroMedix, Inc., Sacron Innovations Pty Ltd., Upstream Medical Technologies Ltd., Immunicom, Inc., Curtana Pharmaceuticals, Inc.; Professor at The University of Queensland; Independent Director at Cardiff Oncology, Inc. since 2020; and Partner & Investment Committee Chair at Pacific Channel Ltd. since 2010.
Former jobs include Chairman & Chief Executive Officer at Waratah Pharmaceuticals, Inc. (2000–2002); President & Chief Executive Officer at SkyePharma Canada, Inc. (1995–2001); Vice Chairman at Hunter Immunology Pty Ltd.; Independent Director at ResMed, Inc. (1994–2018); Director at Imunon, Inc. (2002–2010); Independent Director at Transition Therapeutics, Inc. (2002–2018); Independent Non-Executive Director at Percheron Therapeutics Ltd. (2015–2022); Director at Peplin Ltd. (2009); Independent Non-Executive Director at Guardian Medical Solutions Ltd. (2001–2013); Director at Peplin, Inc. (2004–2009); Independent Non-Executive Director at Invitrocue Ltd. (2018–2019); Director at Breathe Easy Ltd.; Independent Non-Executive Director at Simavita Ltd. (2016–2021); Director at Footfalls & Heartbeats (UK) Ltd. (2013–2015); Director at AVACEN, Inc.; Director at Engender Technologies Ltd.; Independent Director at Pacira Biosciences, Inc. (2008–2024); and Senior Vice President-Research & Development at Clintec International, Inc. (Illinois) (1989–1993).
Education includes a doctorate from Massachusetts Institute of Technology conferred in 1975 and an undergraduate degree from The University of New South Wales conferred in 1974.